Source: https://www.theguardian.com/business/2026/jun/14/london-trial-drug-prevent-cancer-cytokine-storm-poolbeg-pharma From the post: >>A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect. Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage. The drug could also save the NHS and other health systems millions of pounds because those being treated do not have to be supervised in centralised specialist cancer centres in case they succumb to a cytokine storm.